


**Levothyroxine  
EMR 200125-001**

**Bioequiv EMR200125-001 Page 901 of 1628 uation vs. old formulation**

Page 144 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
901/1628



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
904/1628

WV




**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 903 of 1628 ualation vs. old formulation**

Page 146 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
903/1628

M


**Levothyroxine  
EMR 200125-001**

**Bioequiv EMR200125-001 Page 904 of 1628 ulation vs. old formulation**

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Page 147 of 216  
Confidential

Subject ID/Random Number: 5



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
904/1628

WV


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 905 of 1628 ualuation vs. old formulation**

Page 148 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
905/1628

IV

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas


Levothyroxine  
EMR 200125-001

Bioequiv<sup>i</sup> EMR200125-001 Page 909 of 1628 ualuation vs. old formulation

Page 152 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



<sup>i</sup>:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
909/1628

IVI


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 910 of 1628 ualuation vs. old formulation**

Page 153 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



€:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

910/1628

11DEC2014 00:01

AM


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 911 of 1628 ualation vs. old formulation**

Page 154 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
911/1628

IV

**Levothyroxine  
EMR 200125-001**


**Bioequiv: EMR200125-001 Page 912 of 1628 nulation vs. old formulation**

Merck Serono  
EMR 200125-001

Page 155 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION


912/1628

11DEC2014 00:01

AM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



③: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number: 3



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas



**Levothyroxine  
EMR 200125-001**


**Bioequivivalence EMR200125-001 Page 917 of 1628**

Page 160 of 216

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
917/1628

UV

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas


Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
918/1628 

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
920/1628

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: : .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure  
15.4.2.9.sas


**Levothyroxine  
EMR 200125-001**

**Bioequivi EMR200125-001 Page 923 of 1628 ualation vs. old formulation**

Page 166 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas


Document No.0900bab8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
923/1628  
AVI

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
924/1628

AVI

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



⑧Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas



Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: : 2




①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 3



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
928/1628

MM


Levothyroxine  
EMR 200125-001

Bioequiv<sup>t</sup> EMR200125-001 Page 929 of 1628 ualation vs. old formulation

Page 172 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas


Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
929/1628  
MM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
930/1628

AM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Levothyroxine  
EMR 200125-001


Bioequiv<sup>i</sup> EMR200125-001 Page 933 of 1628 ualuation vs. old formulation

Merck Serono  
EMR 200125-001

Page 176 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



①:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas'

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
933/1628

M

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure  
15.4.2.9.sas

Document No.0900bab8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
938/1628

DM  
0V

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 941 of 1628 ualation vs. old formulation**

Page 184 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 10000001



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
941/1628

MM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:




④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
948/1628

SM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Merk Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas


Document No.0900bab8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
952/1628 

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
954/1628

Levothyroxine  
EMR 200125-001


Bioequiv: EMR200125-001 Page 955 of 1628 ualuation vs. old formulation

Page 198 of 216

Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900bab8085bb46 v1.0

CONFIDENTIAL  
INFORMATION


11DEC2014 00:01  
955/1628

Merck Serono  
EMR 200125-001

Page 199 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population).

Subject ID/Random Number: \*\*\*\*\*



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure 15.4.2.9.sas

Document No.0900babeb8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
956/1628

MM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :




④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: .




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001

Page 203 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE 15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION


960/1628

11DEC2014 00:01

AM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



①:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



①:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
962/1628

AVI

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
963/1628

IV

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas


Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
964/1628 

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

**Levothyroxine  
EMR 200125-001**


**Bioequiv: EMR200125-001 Page 967 of 1628 ulation vs. old formulation**

Page 210 of 216

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Document No.0900babec8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

11DEC2014 00:01  
967/1628

WV

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




◊:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



©Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

**Levothyroxine**  
**EMR 200125-001**


Bioequiv: EMR200125-001 Page 970 of 1628 nulation vs. old formulation

Merck Serono  
EMR 200125-001

Page 213 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.9.sas

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION


970/1628

11DEC2014 00:01

MM

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T<sub>4</sub> Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:  
154294



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.


Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number:



⑥Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine  
EMR 200125-001**

Bioequiv: EMR200125-001 Page 975 of 1628 ualation vs. old formulation

Page 2 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

975/1628

AM

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number: 120



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL\_programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.0.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine  
EMR 200125-001

Bioequiv: EMR200125-001 Page 978 of 1628 ultation vs. old formulation

Page 5 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL  
INFORMATION

978/1628

MM


**Levothyroxine  
EMR 200125-001**

Bioequiv: EMR200125-001 Page 980 of 1628 uation vs. old formulation

Page 7 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

980/1628

MI

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine  
EMR 200125-001**

**Bioequiv EMR200125-001 Page 982 of 1628 uation vs. old formulation**

Page 9 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑧:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number:



⑥Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01


Levothyroxine  
EMR 200125-001

Bioequiv: EMR200125-001 Page 987 of 1628 ualuation vs. old formulation

Page 14 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: '



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

987/1628

OMV

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.0.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine  
EMR 200125-001

Bioequiv: EMR200125-001 Page 990 of 1628 vulation vs. old formulation

Page 17 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number:



④:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

990/1628

MI

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.0.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.1.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 995 of 1628 ualation vs. old formulation**

Page 22 of 216  
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T<sub>4</sub> Values) (Safety Population)

Subject ID/Random Number: 103



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine  
EMR 200125-001**

**Bioequiv: EMR200125-001 Page 997 of 1628 uation vs. old formulation**

Page 24 of 216  
Confidential

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1111, 111



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL  
INFORMATION

997/1628

MI

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 114




④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.3.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01

Merck Serono  
EMR 200125-001  
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale  
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.10.sas

11DEC2014 00:01